Jan 24 (Reuters) - Giving COVID-19 vaccines from either AstraZeneca-Oxford, Pfizer-BioNTech or Johnson & Johnson as a booster after two doses of the COVID-19 inactivated-virus vaccine from Sinovac, leads to significantly higher antibodies, a study has found.
The best response was seen when an RNA vaccine was given as a booster after the standard schedule of Sinovac's CoronaVac, researchers from Oxford University said https://www.ox.ac.uk/news/2022-01-24-mixed-vaccine-schedules-offer-strong-booster-responses-after-two-doses-coronavac on Monday, adding that the responses were seen against the Delta and Omicron coronavirus variants too. (Reporting by Aby Jose Koilparambil and Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.)
Our Standards: The Thomson Reuters Trust Principles.
